Boardman and Mangat et al. asked if engineering CAR Treg cells to enhance a suppressive mechanism (IL-10) and simultaneously remove an inhibitory signal (PD-1) would improve their suppressive function. CRISPR-mediated PD-1 deletion increased CAR Treg cell activation, while knock-in of IL-10 into the PDCD1 locus of HLA-A2-specific CAR Tregs (IL-10KITreg), resulted in high levels of antigen-dependent, CAR-regulated IL-10 secretion. IL-10KITreg cells demonstrated increased suppression of dendritic cells and allo-antigen- and islet auto-antigen-specific T cells. In vivo, IL-10KITreg cells were safe, stable, secreted IL-10, and suppressed DCs and xenogeneic GvHD.
Contributed by Katherine Turner
ABSTRACT: Regulatory T cell (T(reg) cell) therapy has been transformed through the use of chimeric antigen receptors (CARs). We previously found that human T(reg) cells minimally produce IL-10 and have a limited capacity to control innate immunity compared to type 1 regulatory T cells (T(r)1 cells). To create "hybrid" CAR T(reg) cells with T(r)1 cell-like properties, we examined whether the PDCD1 locus could be exploited to endow T(reg) cells with CAR-regulated IL-10 expression. CRISPR-mediated PD1 deletion increased CAR T(reg) cell activation, and knock-in of IL10 under control of the PD1 promoter resulted in CAR-induced IL-10 secretion. IL10 knock-in improved CAR T(reg) cell function, as determined by increased suppression of dendritic cells and alloantigen- and islet autoantigen-specific T cells. In vivo, IL10 knock-in CAR T(reg) cells were stable, safe, and suppressed dendritic cells and xenogeneic graft-versus-host disease. CRISPR-mediated engineering to simultaneously remove an inhibitory signal and enhance a suppressive mechanism is a previously unexplored approach to improve CAR T(reg) cell potency.